Is POLB or IXI more profitable?

Poolbeg Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Poolbeg Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Poolbeg Pharma N/A -55.47% -21.33% IXICO -24.98% -16.18% -10.40%

Which has higher earnings & valuation, REDX or IXI?

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Redx Pharma £4.20M 0.00 -£33.16M -£0.10 N/A IXICO £7.28M 2.33 -£3.58M -£1.95 N/A

Is REDX or IXI more profitable?

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Redx Pharma N/A -180.80% -43.95% IXICO -24.98% -16.18% -10.40%

Which has higher valuation and earnings, ETX or IXI?

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio e-therapeutics £295K 0.00 -£10.06M -£0.02 N/A IXICO £7.28M 2.33 -£3.58M -£1.95 N/A

Is ETX or IXI more profitable?

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets e-therapeutics N/A -38.75% -29.10% IXICO -24.98% -16.18% -10.40%

Do analysts prefer HVO or IXI?

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 118.34%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts clearly believe hVIVO is more favorable than IXICO. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score hVIVO 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 IXICO 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, HVO or IXI?

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio hVIVO £46.77M 1.01 £17.84M -£0.87 N/A IXICO £7.28M 2.33 -£3.58M -£1.95 N/A

Is HVO or IXI more profitable?

hVIVO has a net margin of -12.48% compared to IXICO's net margin of -24.98%. hVIVO's return on equity of -14.65% beat IXICO's return on equity. Company Net Margins Return on Equity Return on Assets hVIVO -12.48% -14.65% 11.97% IXICO -24.98% -16.18% -10.40%

Does the media refer more to HVO or IXI?

In the previous week, hVIVO had 3 more articles in the media than IXICO. MarketBeat recorded 4 mentions for hVIVO and 1 mentions for IXICO. IXICO's average media sentiment score of 0.75 beat hVIVO's score of 0.18 indicating that IXICO is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment hVIVO 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral IXICO 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

IXICO (IXI) Competitors

GBX 7.75 +0.25 (+3.33%)

As of 11:25 AM Eastern

Compare

IXI vs. POLB, REDX, ETX, HVO, and HEMO

Should you buy IXICO stock or one of its competitors? IXICO's main competitors and comparable companies include Poolbeg Pharma (POLB), Redx Pharma (REDX), e-therapeutics (ETX), hVIVO (HVO), and Hemogenyx Pharmaceuticals (HEMO). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does IXICO compare to Poolbeg Pharma?

Poolbeg Pharma (LON:POLB) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings, media sentiment and profitability.

Poolbeg Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Poolbeg Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Poolbeg Pharma	N/A	-55.47%	-21.33%
IXICO	-24.98%	-16.18%	-10.40%

IXICO has higher revenue and earnings than Poolbeg Pharma. Poolbeg Pharma is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Poolbeg Pharma	N/A	N/A	-£4.50B	-£0.94	N/A
IXICO	£7.28M	2.33	-£3.58M	-£1.95	N/A

Poolbeg Pharma has a beta of 1.802, meaning that its stock price is 80% more volatile than the broader market. Comparatively, IXICO has a beta of 0.129, meaning that its stock price is 87% less volatile than the broader market.

1.5% of Poolbeg Pharma shares are held by institutional investors. Comparatively, 13.0% of IXICO shares are held by institutional investors. 7.5% of Poolbeg Pharma shares are held by insiders. Comparatively, 3.1% of IXICO shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, IXICO had 1 more articles in the media than Poolbeg Pharma. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Poolbeg Pharma. IXICO's average media sentiment score of 0.75 beat Poolbeg Pharma's score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
Poolbeg Pharma	Neutral
IXICO	Positive

Summary

IXICO beats Poolbeg Pharma on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to Redx Pharma?

Redx Pharma (LON:REDX) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, media sentiment, risk, valuation, dividends and earnings.

72.7% of Redx Pharma shares are held by institutional investors. Comparatively, 13.0% of IXICO shares are held by institutional investors. 18.4% of Redx Pharma shares are held by company insiders. Comparatively, 3.1% of IXICO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, IXICO had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Redx Pharma. IXICO's average media sentiment score of 0.75 beat Redx Pharma's score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
Redx Pharma	Neutral
IXICO	Positive

Redx Pharma has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Redx Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Redx Pharma	N/A	-180.80%	-43.95%
IXICO	-24.98%	-16.18%	-10.40%

IXICO has higher revenue and earnings than Redx Pharma. IXICO is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Redx Pharma	£4.20M	0.00	-£33.16M	-£0.10	N/A
IXICO	£7.28M	2.33	-£3.58M	-£1.95	N/A

Redx Pharma has a beta of -0.53, indicating that its stock price is 153% less volatile than the broader market. Comparatively, IXICO has a beta of 0.129, indicating that its stock price is 87% less volatile than the broader market.

Summary

IXICO beats Redx Pharma on 8 of the 12 factors compared between the two stocks.

How does IXICO compare to e-therapeutics?

e-therapeutics (LON:ETX) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, IXICO had 1 more articles in the media than e-therapeutics. MarketBeat recorded 1 mentions for IXICO and 0 mentions for e-therapeutics. IXICO's average media sentiment score of 0.75 beat e-therapeutics' score of 0.00 indicating that IXICO is being referred to more favorably in the news media.

Company	Overall Sentiment
e-therapeutics	Neutral
IXICO	Positive

e-therapeutics has a beta of 0.46, indicating that its share price is 54% less volatile than the broader market. Comparatively, IXICO has a beta of 0.129, indicating that its share price is 87% less volatile than the broader market.

e-therapeutics has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat e-therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
e-therapeutics	N/A	-38.75%	-29.10%
IXICO	-24.98%	-16.18%	-10.40%

IXICO has higher revenue and earnings than e-therapeutics. IXICO is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
e-therapeutics	£295K	0.00	-£10.06M	-£0.02	N/A
IXICO	£7.28M	2.33	-£3.58M	-£1.95	N/A

26.5% of e-therapeutics shares are owned by institutional investors. Comparatively, 13.0% of IXICO shares are owned by institutional investors. 59.4% of e-therapeutics shares are owned by insiders. Comparatively, 3.1% of IXICO shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

IXICO beats e-therapeutics on 7 of the 12 factors compared between the two stocks.

How does IXICO compare to hVIVO?

hVIVO (LON:HVO) and IXICO (LON:IXI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and media sentiment.

12.7% of hVIVO shares are held by institutional investors. Comparatively, 13.0% of IXICO shares are held by institutional investors. 4.9% of hVIVO shares are held by company insiders. Comparatively, 3.1% of IXICO shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

hVIVO has a net margin of -12.48% compared to IXICO's net margin of -24.98%. hVIVO's return on equity of -14.65% beat IXICO's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
hVIVO	-12.48%	-14.65%	11.97%
IXICO	-24.98%	-16.18%	-10.40%

hVIVO has a beta of 1.706, meaning that its stock price is 71% more volatile than the broader market. Comparatively, IXICO has a beta of 0.129, meaning that its stock price is 87% less volatile than the broader market.

hVIVO presently has a consensus price target of GBX 15, indicating a potential upside of 118.34%. Given hVIVO's stronger consensus rating and higher possible upside, equities analysts clearly believe hVIVO is more favorable than IXICO.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
hVIVO	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.67
IXICO	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, hVIVO had 3 more articles in the media than IXICO. MarketBeat recorded 4 mentions for hVIVO and 1 mentions for IXICO. IXICO's average media sentiment score of 0.75 beat hVIVO's score of 0.18 indicating that IXICO is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
hVIVO	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
IXICO	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

hVIVO has higher revenue and earnings than IXICO. hVIVO is trading at a lower price-to-earnings ratio than IXICO, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
hVIVO	£46.77M	1.01	£17.84M	-£0.87	N/A
IXICO	£7.28M	2.33	-£3.58M	-£1.95	N/A

Summary

hVIVO beats IXICO on 12 of the 16 factors compared between the two stocks.

How does IXICO compare to Hemogenyx Pharmaceuticals?

IXICO (LON:IXI) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends, profitability and media sentiment.

In the previous week, IXICO had 1 more articles in the media than Hemogenyx Pharmaceuticals. MarketBeat recorded 1 mentions for IXICO and 0 mentions for Hemogenyx Pharmaceuticals. IXICO's average media sentiment score of 0.75 beat Hemogenyx Pharmaceuticals' score of 0.00 indicating that IXICO is being referred to more favorably in the media.

Company	Overall Sentiment
IXICO	Positive
Hemogenyx Pharmaceuticals	Neutral

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than IXICO. IXICO is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IXICO	£7.28M	2.33	-£3.58M	-£1.95	N/A
Hemogenyx Pharmaceuticals	N/A	N/A	-£6.89K	-£170.60	N/A

IXICO has a beta of 0.129, suggesting that its share price is 87% less volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.501, suggesting that its share price is 50% more volatile than the broader market.

13.0% of IXICO shares are owned by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are owned by institutional investors. 3.1% of IXICO shares are owned by insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to IXICO's net margin of -24.98%. IXICO's return on equity of -16.18% beat Hemogenyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IXICO	-24.98%	-16.18%	-10.40%
Hemogenyx Pharmaceuticals	N/A	-2,807.75%	-37.79%

Summary

IXICO beats Hemogenyx Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Get IXICO News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IXI vs. The Competition

Export

Metric	IXICO	Biotechnology Industry	Healthcare Sector	LON Exchange
Market Cap	£16.97M	£3.99B	£7.20B	£2.89B
Dividend Yield	1.27%	3.61%	2.53%	6.17%
P/E Ratio	-3.97	12.25	272.63	364.82
Price / Sales	2.33	1,349.92	620.81	83,676.90
Price / Cash	2.25	105.29	76.98	27.89
Price / Book	0.40	16.19	12.85	6.75
Net Income	-£3.58M	-£22.72M	£3.47B	£5.89B
7 Day Performance	2.57%	-1.18%	-0.22%	-0.78%
1 Month Performance	3.33%	12.75%	8.04%	2.38%
1 Year Performance	-36.40%	53.86%	25.08%	22.66%

IXICO Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IXI IXICO	N/A	GBX 7.75 +3.3%	N/A	-35.0%	£16.97M	£7.28M	N/A	89	Gap Up
POLB Poolbeg Pharma	N/A	GBX 8.59 +1.0%	N/A	+160.1%	£64.89M	N/A	N/A	12	High Trading Volume
REDX Redx Pharma	N/A	N/A	N/A	N/A	£58.35M	£4.20M	N/A	101	Gap Up High Trading Volume
ETX e-therapeutics	N/A	N/A	N/A	N/A	£52.59M	£295K	N/A	35	High Trading Volume
HVO hVIVO	1.6578 of 5 stars	GBX 6.43 -1.8%	GBX 15 +133.5%	-32.2%	£45.02M	£46.77M	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:IXI) was last updated on 9/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IXICO (IXI) Competitors

IXI vs. POLB, REDX, ETX, HVO, and HEMO

How does IXICO compare to Poolbeg Pharma?

Summary

How does IXICO compare to Redx Pharma?

Summary

How does IXICO compare to e-therapeutics?

Summary

How does IXICO compare to hVIVO?

Summary

How does IXICO compare to Hemogenyx Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXI vs. The Competition

IXICO Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

IXICO (IXI) Competitors

IXI vs. POLB, REDX, ETX, HVO, and HEMO

How does IXICO compare to Poolbeg Pharma?

Is POLB or IXI more profitable?

Which has preferable valuation and earnings, POLB or IXI?

Which has more risk & volatility, POLB or IXI?

Do insiders & institutionals have more ownership in POLB or IXI?

Does the media prefer POLB or IXI?

Summary

How does IXICO compare to Redx Pharma?

Do insiders & institutionals believe in REDX or IXI?

Does the media favor REDX or IXI?

Is REDX or IXI more profitable?

Which has higher earnings & valuation, REDX or IXI?

Which has more volatility & risk, REDX or IXI?

Summary

How does IXICO compare to e-therapeutics?

Does the media refer more to ETX or IXI?

Which has more volatility and risk, ETX or IXI?

Is ETX or IXI more profitable?

Which has higher valuation and earnings, ETX or IXI?

Do institutionals and insiders hold more shares of ETX or IXI?

Summary

How does IXICO compare to hVIVO?

Do insiders & institutionals believe in HVO or IXI?

Is HVO or IXI more profitable?

Which has more volatility and risk, HVO or IXI?

Do analysts prefer HVO or IXI?

Does the media refer more to HVO or IXI?

Which has better valuation and earnings, HVO or IXI?

Summary

How does IXICO compare to Hemogenyx Pharmaceuticals?

Does the media prefer IXI or HEMO?

Which has preferable valuation and earnings, IXI or HEMO?

Which has more volatility & risk, IXI or HEMO?

Do institutionals and insiders have more ownership in IXI or HEMO?

Is IXI or HEMO more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXI vs. The Competition

IXICO Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools